AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T20:18:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
3 Mid-Cap Stocks with Questionable Fundamentals
Thu 15 May 25, 04:35 AMIncyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
Wed 14 May 25, 11:49 AMINCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance
Tue 13 May 25, 10:44 AMWhat To Expect From Natera’s (NTRA) Q1 Earnings
Wed 07 May 25, 07:12 AMQ1 2025 Syndax Pharmaceuticals Inc Earnings Call
Tue 06 May 25, 05:13 PMWhy Low-Debt Stocks Are the Way to Go
Tue 06 May 25, 09:51 AMHigh Growth Tech Stocks in US with Strong Potential for Investors
Fri 02 May 25, 11:38 AMIncyte First Quarter 2025 Earnings: Beats Expectations
Wed 30 Apr 25, 11:19 AMIncyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
Wed 30 Apr 25, 07:06 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 529.12M | 570.44M | -232.21800M | 486.79M | 115.35M |
| Minority interest | - | - | - | - | - |
| Net income | 340.66M | 948.58M | -295.69700M | 446.91M | 109.49M |
| Selling general administrative | 1002.10M | 739.60M | 516.90M | 468.71M | 434.41M |
| Selling and marketing expenses | 0.04M | -0.04000M | 0.02M | - | - |
| Gross profit | 3187.64M | 2835.28M | 2535.37M | 2044.51M | 1787.76M |
| Reconciled depreciation | 67.86M | 57.84M | 51.81M | 54.53M | 54.97M |
| Ebit | 579.44M | 585.78M | -240.29100M | 402.01M | 132.19M |
| Ebitda | 631.52M | 611.16M | -217.08500M | 473.87M | 187.16M |
| Depreciation and amortization | 52.08M | 25.39M | 23.21M | 71.86M | 54.97M |
| Non operating income net other | 39.93M | 10.65M | 23.21M | 52.18M | 31.76M |
| Operating income | 579.44M | 585.78M | -240.29100M | 402.01M | 129.22M |
| Other operating expenses | 2803.05M | 2385.75M | 2906.99M | 1737.07M | 1726.49M |
| Interest expense | 2.67M | 1.91M | 2.17M | 1.85M | 1.54M |
| Tax provision | 188.46M | -378.13700M | 63.48M | 39.88M | 5.85M |
| Interest income | - | - | - | 84.78M | 45.64M |
| Net interest income | -2.66600M | -1.90800M | -2.17400M | -1.85500M | -1.54300M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 188.46M | -378.13700M | 63.48M | 39.88M | 5.85M |
| Total revenue | 3394.64M | 2986.27M | 2666.70M | 2158.76M | 1881.88M |
| Total operating expenses | 2596.05M | 2234.76M | 2775.66M | 1622.82M | 1632.36M |
| Cost of revenue | 207.00M | 150.99M | 131.33M | 114.25M | 94.12M |
| Total other income expense net | -50.32400M | -15.33300M | 8.07M | 84.78M | -38.50600M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 340.66M | 948.58M | -295.69700M | 446.91M | 109.49M |
| Net income applicable to common shares | 340.66M | 948.58M | -295.69700M | 446.91M | 109.49M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 6782.11M | 5840.98M | 4933.35M | 3560.92M | 3426.75M |
| Intangible assets | 123.55M | 129.22M | 150.75M | 172.29M | 193.83M |
| Earning assets | - | - | - | - | - |
| Other current assets | 182.83M | 167.01M | 165.30M | 103.31M | 94.18M |
| Total liab | 1592.27M | 1470.87M | 1163.35M | 949.65M | 828.34M |
| Total stockholder equity | 5189.84M | 4370.12M | 3770.00M | 2611.27M | 2598.41M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 111.75M | 469.74M | 82.76M | 86.21M | 76.06M |
| Common stock | 0.22M | 0.22M | 0.22M | 0.22M | 0.22M |
| Capital stock | 0.22M | 0.22M | 0.22M | 0.22M | 0.22M |
| Retained earnings | 160.38M | -437.21400M | -777.87400M | -1726.45500M | -1430.75800M |
| Other liab | - | 269.60M | 244.00M | 266.00M | 271.23M |
| Good will | 155.59M | 155.59M | 155.59M | 155.59M | 155.59M |
| Other assets | - | 564.04M | 467.54M | 25.15M | 55.56M |
| Cash | 3213.38M | 2951.42M | 2057.44M | 1513.01M | 1832.68M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1240.38M | 1216.60M | 885.08M | 648.79M | 500.46M |
| Current deferred revenue | 1009.91M | 457.94M | 617.02M | 448.86M | 312.44M |
| Net debt | -3175.08900M | -2906.78600M | -2023.17300M | -1478.15100M | -1781.80200M |
| Short term debt | 9.12M | 11.37M | 13.19M | 14.96M | 28.31M |
| Short long term debt | - | - | - | - | 18.30M |
| Short long term debt total | 38.29M | 44.64M | 34.27M | 34.86M | 50.88M |
| Other stockholder equity | 5016.12M | 4792.04M | 4567.11M | 4352.86M | 4044.49M |
| Property plant equipment | - | 739.31M | 723.92M | 559.62M | 377.57M |
| Total current assets | 4645.40M | 4198.95M | 3186.73M | 2422.66M | 2537.05M |
| Long term investments | 187.72M | 133.68M | 221.27M | 222.30M | 133.66M |
| Net tangible assets | - | 4085.31M | 3463.66M | 2283.38M | 2248.99M |
| Short term investments | 442.67M | 287.54M | 290.75M | 288.37M | 284.87M |
| Net receivables | 743.56M | 644.88M | 616.30M | 481.99M | 308.81M |
| Long term debt | - | - | - | - | 18.30M |
| Inventory | 62.97M | 120.96M | 56.94M | 35.97M | 16.50M |
| Accounts payable | 109.60M | 277.55M | 172.11M | 98.77M | 83.65M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 13.11M | 15.07M | -19.45400M | -15.36000M | -15.54200M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.22M | 0.22M | 0.22M | 0.22M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -437.21400M | -777.87400M | -1726.45500M | -1430.75800M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 260.92M | 106.10M | 68.06M | 62.76M | 55.56M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 2136.70M | 1642.04M | 1746.62M | 1138.26M | 889.70M |
| Capital lease obligations | 38.29M | 41.46M | 44.82M | 47.53M | 41.92M |
| Long term debt total | - | - | - | - | 31.92M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.70900M | -26.69300M | -81.62200M | -9.39000M | -12.94000M |
| Change to liabilities | 325.63M | 204.78M | 128.96M | 58.86M | 24.13M |
| Total cashflows from investing activities | -78.54200M | -207.69900M | -269.00100M | -87.45400M | -86.42300M |
| Net borrowings | -2.86200M | -2.41700M | -0.83600M | -0.82200M | -0.82200M |
| Total cash from financing activities | -0.79400M | 6.18M | 71.71M | 45.71M | 14.66M |
| Change to operating activities | 189.46M | 67.36M | 105.79M | 84.79M | -45.43900M |
| Net income | 340.66M | 948.58M | -295.69700M | 446.91M | 109.49M |
| Change in cash | 893.96M | 544.39M | -318.94200M | 668.72M | 264.55M |
| Begin period cash flow | 2059.16M | 1514.77M | 1833.71M | 1164.99M | 900.43M |
| End period cash flow | 2953.12M | 2059.16M | 1514.77M | 1833.71M | 1164.99M |
| Total cash from operating activities | 969.94M | 749.49M | -124.59900M | 710.66M | 336.23M |
| Issuance of capital stock | - | - | - | 0.00000M | 0.00000M |
| Depreciation | 67.86M | 57.84M | 51.81M | 54.53M | 54.97M |
| Other cashflows from investing activities | - | - | - | -9.39000M | -12.94000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -67.50400M | -20.96500M | -19.46800M | -6.10000M | 4.04M |
| Change to account receivables | -28.57900M | -134.30600M | -173.18500M | -1.21100M | -41.29900M |
| Sale purchase of stock | 61.12M | 58.63M | 110.31M | 63.30M | 29.94M |
| Other cashflows from financing activities | -59.04700M | -50.03300M | -37.76000M | -16.76600M | -52.10700M |
| Change to netincome | 275.03M | -266.44000M | 201.46M | 186.38M | 174.21M |
| Capital expenditures | 77.83M | 181.01M | 187.38M | 78.06M | 73.48M |
| Change receivables | -28.57900M | -134.30600M | -173.18500M | -1.21100M | -41.29900M |
| Cash flows other operating | 56.85M | -40.00800M | -18.47600M | -28.71400M | 10.68M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 890.61M | 547.97M | -321.89100M | 668.91M | 264.46M |
| Change in working capital | 198.81M | -14.56900M | -71.74100M | 57.30M | -46.53900M |
| Stock based compensation | 188.42M | 183.01M | 177.88M | 166.59M | 148.15M |
| Other non cash items | 117.11M | 40.23M | 13.51M | -14.29000M | 70.61M |
| Free cash flow | 892.11M | 568.48M | -311.97800M | 632.59M | 262.74M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| INCY Incyte Corporation |
-1.08 1.11% | 96.02 | 17.35 | 11.39 | 3.27 | 2.33 | 2.29 | 9.22 |
| NVO Novo Nordisk A/S |
-1.06 2.66% | 38.72 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
- -% | 38.88 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
38.30 8.31% | 499.17 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-9.57 1.22% | 772.03 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
| Name | Title | Year Born |
|---|---|---|
| Mr. Herve Hoppenot | Chairman, Pres & CEO | 1960 |
| Ms. Christiana Stamoulis MBA | Exec. VP & CFO | 1971 |
| Ms. Maria E. Pasquale J.D. | Exec. VP, Gen. Counsel & Corp. Sec. | 1966 |
| Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D. | Exec. VP & GM of North America | 1958 |
| Dr. Steven H. Stein M.D. | Exec. VP & Chief Medical Officer | 1967 |
| Mr. Thomas Tray | VP of Fin., Chief Accounting Officer & Controller | 1978 |
| Mr. Michael James Morrissey | Exec. VP & Head of Global Technical Operations | 1964 |
| Dr. Dashyant Dhanak Ph.D. | Exec. VP & Chief Scientific Officer | 1961 |
| Ms. Christine Chiou | Head of Investor Relations | NA |
| Ms. Pamela M. Murphy | VP of Investor Relations & Corp. Communications | 1951 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...